Key takeaways
- Europe’s biggest challenge is no longer developing biobased technologies. It is creating the commercial conditions needed to scale them.
- Policy fragmentation, inconsistent standards, and limited market-pull mechanisms continue to slow commercialization across the European bioeconomy.
- Financing first-of-a-kind (FOAK) facilities remains one of the largest barriers between pilot success and commercial deployment.
- Corporate sustainability goals alone are not driving widespread adoption of biobased products. Performance, cost, and supply security remain the primary purchasing criteria.
- Innovation leaders should evaluate European biobased companies based on commercialization readiness, not just technology maturity.
The Lux Take: Europe’s commercialization gap
Europe no longer lacks biobased innovation; it lacks the commercial conditions needed to deploy it at scale. Clients evaluating innovators in the region should focus less on technology readiness and more on indicators of commercial maturity, including long-term offtake agreements, strategic partnerships, and access to scale-up capital.
From June 10 to June 11, 2026, Lux attended Bio Innovations Europe in The Hague, Netherlands, an exhibition and networking event focused on making “bio the new normal.” The conference convened startups, corporates, investors, policymakers, and plant operators. Sessions covered biomanufacturing applications in textiles, food, and packaging, alongside broader challenges around scale-up, financing, standards, and downstream market access. Across more than 30 presentations and panel discussions, the key message was clear: Europe’s bioeconomy is producing credible technical innovation, but policy fragmentation, FOAKplant financing gaps, and uneven downstream demand still constrain commercialization.
Here are the three biggest takeaways from the event:
1. Europe is generating biobased innovation but struggling to commercialize it
Throughout the conference, policymakers, investors, and technology developers repeatedly highlighted that Europe does not suffer from a lack of innovation in industrial biotechnology. Instead, the region struggles with translating promising technologies into commercial-scale manufacturing and market adoption. Claire Skentelbery, Ph.D., director general of EuropaBio, captured this sentiment during her presentation, noting that “the science is 5%; the remaining 95% is dictated by legislation.” Discussions surrounding the forthcoming EU Biotech Act II suggested that policymakers increasingly recognize this challenge. While the first Biotech Act largely established a strategic framework for biotechnology in healthcare, the second iteration is expected to place greater emphasis on industrial biotechnology and biomanufacturing, financing mechanisms, workforce development, microbiology, and public awareness. Attendees also referenced broader European initiatives, including the European Innovation Act, the proposed European Competitiveness Fund, and recommendations from the Draghi report on European competitiveness and Enrico Letta’s “Much More Than a Market” report, both of which call for reducing fragmentation, mobilizing investment, and strengthening Europe’s ability to scale strategic industries. Collectively, these initiatives signal that government stakeholders increasingly view biotechnology as an industrial competitiveness issue rather than solely an innovation-policy issue.
But translating this policy ambition into commercial deployment remains a challenge. Several attendees highlighted that market adoption continues to lag technological progress, arguing that voluntary sustainability commitments alone are unlikely to drive widespread adoption of biobased materials. Instead, stronger market-pull measures, including binding biobased-content requirements, will be necessary to create predictable demand. Participants pointed out that inconsistencies in the definitions of biobased materials, alternative feedstocks, and chain-of-custody models across regions have raised obstacles. While these issues may appear administrative, they create significant complexity for companies attempting to scale production, certify products, and access international markets.
2. Financing first-of-a-kind facilities remains Europe’s biggest commercialization hurdle
Financing discussions focused less on VC availability and more on the demonstration-stage investment bottleneck. Several attendees described the transition from pilot facilities to FOAK plants as the hardest phase of commercialization. Marc den Hartog, CEO of ChainCraft, highlighted that demo-scale facilities remain particularly challenging to finance despite being essential for validating economics and reducing scale-up risk before commercial deployment. Marco Jansen, chief commercial and public affairs officer at Avantium, discussed similar challenges. The company has invested approximately EUR 200 million in a flagship plant to produce 2,5-furandicarboxylic acid, and while it expects to commission the facility by the end of 2026, the plant has been in development for nearly a decade and is still prerevenue and unprofitable. The example underscores the long timelines and difficult economics associated with FOAK biomanufacturing assets and the need for patient capital.
Investors echoed similar concerns. Ward Heij, business development manager at Colesco Capital Circular & Climate Credit Impact Fund, noted that securing project equity will become increasingly difficult under current macroeconomic conditions. Discussions repeatedly returned to the challenge of allocating risk across the value chain. Investors are often reluctant to finance projects without a secured feedstock supply, long-term offtake agreements, or strategic partners willing to share commercialization risk. Several attendees argued that Europe has built a strong funding ecosystem for early stage innovation through programs like Horizon Europe, but comparable support mechanisms for demo and FOAK assets remain limited. As a result, many attendees called for a combination of patient capital, public–private financing structures, and targeted policy support to bridge the commercialization gap. The broader sentiment was that Europe does not lack technologies capable of reaching commercial readiness; rather, it lacks financing structures to support the final, most capital-intensive stages of deployment.
3. Sustainability alone is not driving adoption of biobased products
Discussions throughout the event suggested that corporate sustainability targets are not translating into rapid adoption of biobased ingredients or materials. Fabien Deswarte, head of strategic partnerships for the Sustainability Group at L’Oréal, underscored this gap, noting that despite more than three decades of sustainability programs and a target for 75% of ingredients to come from renewable, biobased, recycled, mineral, or alternative carbon sources by 2030, increasing the company’s share of naturally derived ingredients from 59% to 67% took five years of sustained effort. The example highlights that even motivated brands face practical barriers around formulation, sourcing, validation, cost, and performance. Across the event, attendees emphasized that sustainability alone rarely justifies switching ingredients; future adoption will depend more on biobased products that offer multifunctionality, performance advantages, or other clear benefits that can support premium pricing and reduce switching risk.
This challenge extends beyond consumer products. UPM argued that biobased technologies scale only when broader market structures reward adoption, not simply when sustainability commitments exist. The bioplastics sector illustrates this gap clearly: European Bioplastics noted that bioplastics still represent only around 0.5% of global plastics production. Customers continue to prioritize performance, reliability, and cost, with sustainability serving as an additional purchasing criterion rather than the primary driver. As a result, developers will be better positioned when biobased products offer clear performance, cost, supply-security, or regulatory advantages in addition to sustainability benefits.
Outlook: What innovation leaders should watch in Europe’s bioeconomy
Bio Innovations Europe 2026 reinforced several messages that Lux has observed repeatedly across the biobased chemicals and materials domain. Specifically for Europe, that technological readiness is increasingly outpacing the policy, financing, and market structures needed for large-scale deployment. Europe has the resources necessary to build a globally competitive bioeconomy, notably strong research centers, advanced industrial infrastructure, and a growing policy focus on biotechnology. But fragmented regulations, weak market-pull mechanisms, and an underdeveloped financing ecosystem for FOAK facilities continue to hamper commercialization.
Clients should pay particular attention to developments surrounding the EU Biotech Act II and broader European competitiveness initiatives over the next two years. These measures aren’t likely to solve commercialization challenges in the near term, but they could begin to address structural barriers repeatedly identified during the event and those that the overall industry continues to face. More importantly, clients should avoid viewing scale-up risk solely through a technology lens. The companies most likely to succeed will be those that secure downstream demand, establish risk-sharing partnerships across the value chain, and position themselves within markets where policy support, financing, and customer adoption are beginning to converge.
Learn what’s next for chemicals innovation
Want a broader perspective on where the chemicals industry is heading? Explore Lux’s report “The Next Era of Chemicals Innovation” to understand the technologies, market forces, and strategic priorities shaping innovation across chemicals, materials, and industrial biotechnology. Discover where investment is accelerating, which trends matter most, and how to position your innovation strategy for long-term growth.